FDA concerned over foreign trials data

Share this article:
As more companies outsource expensive human clinical trials to lower-cost foreign sites, the FDA says it is confronting "huge" challenges in the safety and effectiveness of data that come back to the US for review.

These problems run the gamut from ethical and medical practice standards to site-inspection travel costs to reading case reports in unfamiliar languages.

“The challenges are huge, and they include issues related to human subject protection, making sure that the standards that we expect trials to be conducted under are adhered to in countries that were less often used for clinical trials in the past,” according to the FDA's director of new drugs, John Jenkins.

Addressing a Drug Information Association “town meeting” in Philadelphia on June 22, Jenkins said the trend has also caused FDA to worry about the validity of data gathered among foreign populations data when extrapolated to the US population.

FDA associate director for medical policy Robert Temple offered that the trend is making FDA “nervous” because of patient “subset” differences in drug responses between ethnicities and different cultures that can emerge. “They may or may not be real,” he said, “but when a study from Serbia drives the whole study, I have to tell you it provokes some nervousness.”

Temple said that US clinical trial investigators can be barred from further service, or even jailed. “So we think it's not a bad idea to have clearly US data most of the time.”

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...